Rodríguez BS, Almeida GJ

Idioma: Español
Referencias bibliográficas: 23
Paginas: 126
Archivo PDF: 272.64 Kb.

FRAGMENTO

Sr. Editor:
Hemos leído con interés el artículo de los doctores Gómez Recio y Lázaro García, publicado en CorSalud, y no coincidimos con sus planteamientos debido a la controversia existente en este tema; razón por la cual se emiten los siguientes comentarios.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gómez Recio M, Lázaro García R. Por qué usar pre-ferentemente stents no farmacoactivos. CorSalud [Internet]. 2013 [Citado 2013 Nov 11];5(4):321-324. Disponible en:

2. http://www.corsalud.sld.cu/pdf/2013/v5n4a13/es/bms.pdf

3. Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, et al. Three-year out-come of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocar-dial infarction (from the MISSION! Intervention Study). Am J Cardiol. 2010;106(1):4-12.

4. Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial in-farction) trial. J Am Coll Cardiol. 2010;55(8):810-4.

5. Di Lorenzo E, Sauro R, Varricchio A, Capasso M,

6. Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009;158(4): e43-50.

7. de la Torre Hernández JM, Díaz Fernández JF, Saba-té Tenas M, Goicolea Ruigómez J. Actualización en cardiología intervencionista. Rev Esp Cardiol. 2012; 65(Supl. 1):4-11.

8. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011;4(1):24-9.

9. Piccolo R, Cassese S, Galasso G, De Rosa R, D'Anna C, Piscione F. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Atherosclerosis. 2011;217(1):149-57.

10. Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(8):977-87.

11. Wallace EL, Abdel-Latif A, Charnigo R, Moliterno DJ, Brodie B, Matnani R, et al. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(7):932-40.

12. 10.De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172(8):611-21.

13. 11.Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. JACC Cardiovasc Interv. 2012;5(3):313-22.

14. 12.Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62(6):496-504.

15. 13.Lindefjeld DS, Guarda E, Méndez M, Martínez A, Pérez O, Fajuri A, et al. Microvascular coronary flow comparison in acute myocardial infarction angio-plasty treated with a mesh covered stent (MGUARD stent) versus bare metal stent: MICAMI-MGUARD. Cardiovasc Revasc Med. 2013;14(1):4-8.

16. 14.Costa JR, Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGuard for

17. acute ST elevation reperfusion MASTER trial. Cathe-ter Cardiovasc Interv. 2013;82(2):184-90.

18. 15.Sciahbasi A, Pendenza G, Golino L, Romagnoli E, Ca-ferri G, Patrizi R, et al. Closed versus open cell stent for high-risk percutaneous coronary interventions in ST-elevation acute myocardial infarction: the Closed versus Open Cells stent for High risk percu-taneous coronary Interventions in ST-Elevation acute myocardial infarction (COCHISE) pilot study. Am Heart J. 2013;165(3):415-20.

19. 16.Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59(23): 2051-7.

20. 17.Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yaz-dani SK, Ladich E, et al. The pathology of neoathe-rosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011; 57(11):1314-22.

21. 18.Vink MA, Dirksen MT, Tijssen JG, Suttorp MJ, Patterson MS, van Geloven N, et al. Lack of long-term clinical benefit of thrombus aspiration during primary percutaneous coronary intervention with paclitaxel-eluting stents or bare-metal stents: post-hoc analysis of the PASSION-trial. Catheter Cardio-vasc Interv. 2012;79(6):870-7.

22. 19.Escaned J, Echavarría-Pinto M, Gorgadze T, Gonzalo N, Armengol F, Hernández R, et al. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention. 2013;8(10):1149-56.

23. 20.Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, et al. Intracoronary abcixi-mab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307(17):1817-26.